Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
-
-
-
-
-
-
-
Ladenburg Thalmann Assumes UroGen Pharma (URGN) at Buy
-
-
-
-
-
-
-
UroGen launches ZUSDURI as revenue rises 21% in 2025
-
-
-
-
-
-
-
Piper Sandler Starts UroGen Pharma (URGN) at Overweight
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
-
-
-
-
-
-
-
URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
-
-
-
-
-
-
URGN LEGAL ALERT: BFA Law Notifies UroGen Pharma Ltd. Investors of the Imminent July 28 Securities Fraud Class Action Deadline
-
433,582 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

